ArcadiusXP L Post Market Clinical Follow-Up (ArcadiusXPLPMS)
Clinical Follow-up of the ArcadiusXP L Stand Alone Intervertebral Body Fusion Device
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Kremmen, Germany, 16766
- Sana Kliniken Sommerfeld
-
Lingen, Germany, 49808
- St. Bonifatius Hospital Lingen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- all indications as given by the instructions for use
- Patients with persisting lumbosacral and pseudo-radicular pain scheduled for monosegmental lumbar interbody fusion from L4 to S1
- Age 18 - 60
- at least 6 months of unsuccessful treatment including conservative measures
- Non-sequestrated and subligamentous prolapse
Exclusion Criteria:
- all contraindications, which are listed in the instructions for use.
- existing pregnancy, planned or occurring during study period
- patients with a higher degree of segmental degeneration in other than the segment to be operated
- body- mass-index (BMI) > 30
- Systemic or local infection
- Increased risk of osteoporosis according to assessment by the SCORE evaluation
- Bone metabolism disorders
- Chemotherapy or radiotherapy (ongoing or planned)
- Participation in another clinical trial
- Scheduled for spinal litigation
- Other serious conditions that hinder the participation in the study
- Nanogel® filling of the cage, prior to implantation was not done
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ODI (2y) - ODI(preop)
Time Frame: 2 years
|
Difference between Oswestry Disability Index (ODI) at 2 years and preoperative ODI
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fusion/arthrodesis status, and further radiological documentation of operated and adjacent levels
Time Frame: 2 years
|
Angle difference in flexion and extension radiographs at each timepoint; analysis of AP and ML x-rays regarding changes in bone density (identification of bone bridges): CT/MRT are considered when available; consideration of pot.
radiolucencies around the
|
2 years
|
|
Overall success
Time Frame: 2 years
|
ODI at each timepoint
|
2 years
|
|
Overall success
Time Frame: 2 years
|
|
2 years
|
|
Pain (back and leg)
Time Frame: 2 years
|
Pain levels (back and leg) as measured via Visual Analogue scale (VAS) at each timepoint
|
2 years
|
|
Adverse events
Time Frame: 2 years
|
2 years
|
|
|
Patient satisfaction
Time Frame: 2 years
|
"Would you have the Operation again?"
|
2 years
|
|
Concomitant pain medication
Time Frame: 2 years
|
Documentation of drug related medication
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Peter Douglas Klassen, MD (PY), St. Bonifatius Hospital Lingen
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AAG-O-H-1227
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.